Low-dose topiramate in adults with treatment-resistant partial-onset seizures

Acta Neurologica Scandinavica

Volumn 106, Issue 4, 2002, Pages 183-189

  Guberman, A ^a   Neto, W ^b   Gassmann Mayer, C ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Epilepsy; Low dose; Partial onset; Topiramate

Indexed keywords

CARBAMAZEPINE; PLACEBO; TOPIRAMATE;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVOUSNESS; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CARBAMAZEPINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0036785082     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2002.02071.x     Document Type: Article

References (24)

1. LEPPIK I. AED doses: from animals to humans. In: FRENCH J, LEPPIK I, DICHTER MA, eds. Advances in neurology. Philadelphia: Lippincott-Raven Publishers, 1998, Vol. 76, pp. 89-93.
2. FAUGHT E, WILDER BJ, RAMSAY RE et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996;46:1684-90.
3. PRIVITERA M, FINCHAM R, PENRY J et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996;46:1678-83.
4. SHARIEF M, VITERI C, BEN-MENACHEM E et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24.
5. TASSINARI CA, MICHELUCCI R, CHAUVEL P et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
6. BEN-MENACHEM E, HENRIKSEN O, DAM M et al. Double-blind, placebo controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43.
7. REIFE R, PLEDGER G, WU SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000;41(Suppl. 1):S66-71.
8. YEN DJ, YU HY, GUO YC, CHEN C, YIU CH, SU MS. A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia 2000;41:1162-6.
9. STEPHEN LJ, SILLS GJ, BRODIE MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000;41:977-80.
10. WHEELER SD, CARRAZANA EJ. Topiramate-treated cluster headache. Neurology 1999;53:234-6.
11. LETMAIER M, SCHREINZER D, WOLF R, KASPER S. Topiramate as a mood stabilizer. Int Clin Psychopharmacol 2001;16:295-8.
12. BITON V, EDWARDS KR, MONTOURIS GD, SACKELLARES JC, HARDEN CL, KAMIN M. Topiramate titration and tolerability. Ann Pharmacother 2001;35:173-9.
13. SVENDSEN T, JOHANNESSEN SI, DAHL R. Topiramate in refractory epilepsy. Epilepsia 1998;39(Suppl. 6):56.
14. PETROFF OA, HYDER F, ROTHMAN DL, MATTSON RH. Topiramate rapidly raises brain GABA in epilepsy patients. Epilepsia 2001;42:543-8.
15. PETROFF OA, HYDER F, MATTSON RH, ROTHMAN DL. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology 1999;52:473-8.
16. PETROFF OA, ROTHMAN DL, BEHAR KL, HYDER F, MATTSON RH. Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. Seizure 1999;8:120-7.
17. PETROFF OA, HYDER F, ROTHMAN DL, MATTSON RH. Homocarnosine and seizure control in juvenile myoclonic epilepsy and complex partial seizures. Neurology 2001; 56:709-15.
18. SACHDEO RC, SACHDEO SK, WALKER SA, KRAMER LD, NAYAK RK, DOOSE DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:774-80.
19. GISCLON LG, CURTIN CR, KRAMER LD. The steady-state (SS) pharmakokinetics (PK) of phenytoin (Dilantin®) and topiramate (TOPAMAX™) in epileptic patients on monotherapy, and during combination therapy. Epilepsia 1994;35(Suppl. 8):54.
20. GILLIAM F, REIFE R, WU SC. Topiramate monotherapy: randomized controlled trial in patients with newly diagnosed epilepsy. Neurology 1999;52(Suppl. 2):A248.
21. BRODIE MJ, RICHENS A, YUEN AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995;345:476-9.
22. STEINER TJ, DELLAPORTAS CI, FINDLEY LJ et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40:601-7.
23. PRIVITERA MD, BRODIE MJ, NETO W, WANG S. Topiramate, carbamazepine, and valproate in the spectrum of newly diagnosed epilepsy. Neurology 2001;56(Suppl. 3):A332.
24. ALAPATI A, FAUGHT E. Side effect profile on two different starting doses of topiramate. Epilepsia 1999;40(Suppl. 7):141-2.